Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa

Archives of Internal Medicine

Volumn 159, Issue 10, 1999, Pages 1127-1132

  Carmeli, Yehuda ^a,b   Troillet, Nicolas ^a,c   Karchmer, Adolf W ^a   Samore, Matthew H ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c Ctrl Inst of the Valais Hospitals   (Switzerland)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; TREATMENT PLANNING;

ADULT; AGED; BACTEREMIA; BOSTON; DRUG RESISTANCE, MICROBIAL; FEMALE; HOSPITAL BED CAPACITY, 300 TO 499; HOSPITAL CHARGES; HOSPITAL MORTALITY; HOSPITALS, TEACHING; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK;

EID: 0033599982     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.10.1127     Document Type: Article

References (27)

1. Acar JF. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis. 1997;24(suppl 1):S17-S18.
2. Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992;257:1050-1055.
3. Impacts of Antibiotic-Resistant Bacteria: Thanks to Penicillin - He Will Come Home! Washington, DC: Office of Technology Assessment, Congress; 1995. Publication OTA-H-629.
4. Holemberg SD, Solomon SL, Blake PA. Health and economic impact of antimicrobial resistance. Rev Infect Dis. 1987;9:1065-1078.
5. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991; 115:585-590.
6. Davis JE. Resistance to aminoglycosides: mechanism and frequency. Rev Infect Dis. 1983;5(suppl 2):S261-S267.
7. Hospital Infections Program, Centers for Disease Control and Prevention. NNIS Antimicrobial Resistance Surveillance Report, May 1996. Available at: http:// www.cdc.gov/ncidod/diseases/hip/hipmenu.htm. Accessed September 1997.
8. Basustaoglu AC, Gun H, Saracli MA, Baysallar M, Haznedaroglu T. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1995;14:469-470.
9. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis. 1994;170: 1622-1625.
10. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility pattern. Clin Infect Dis. 1997;25: 1094-1098.
11. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol. 1987;6:234-244.
12. Quinn JP, Dudek EJ, DiVincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986;154:289-294.
13. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother. 1994;38:547-557.
14. Pechere JC, Vladoianu IR. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother. 1992; 29:563-573.
15. Carmeli Y, Troillet N, Ellopoulos GM, Samore MH. Emergence of antibiotic resistant Pseudomonas aeruginosa: the association with various antipseudomonal agents. Clin Infect Dis. 1997;25:435.
16. Troillet N, Jaccard C, Commeta A, Bille A, Glauser MP. Emergence of resistant Pseudomonas aeruginosa during imipenem vs. piperacillin-tazobactam therapy. Clin Microbiol Infect. 1997;3(suppl 2):177.
17. Iten A, Cometta A, Moreillon P, Eggimann P, Siegrist H, Francioli P. Addition of netilmicin to imipenem does not prevent the emergence of imipenem-resistance during treatment of severe infections. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996; New Orleans, La. Abstract C112.
18. Manian FA, Meyer L, Jenne J, Owen A, Taff T. Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units. Infect Control Hosp Epidemiol. 1996;17:322-226.
19. Samore M, Lichtenberg D, Sauberman L, Kawachi C, Carmeli Y. A clinical data repository enhances hospital infection control. Proc AMIA Annu Fall Symp. October 1997;9:56-60.
20. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-140.
21. Phelps CE. Bug/drug resistance: sometimes less is more. Med Care. 1989;27: 194-203.
22. Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis. 1988;10:629-635.
23. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621-1629.
24. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Murder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87:540-546.
25. Celis R, Torres A, Gatell JM, Almela M, Rodrigues-Roisin R, Agusti-Vidal A. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest. 1988; 93:318-324.
26. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med. 1996;156:2121-2126.
27. Iezzoni LI. The risks of risk adjustment. JAMA. 1997;278:1600-1607.